Creatine-Guanidinoacetic Acid Supplementation for Sarcopenia (CREGAAS)

Not Applicable

Completed

• Conditions: Sarcopenia
• Interventions: Dietary Supplement: Creatine-guanidinoacetic acid; Other: Inulin

• Registration Number: NCT04652921
• Lead Sponsor: University of Novi Sad, Faculty of Sport and Physical Education

Brief Summary

Sarcopenia-driven brain and muscle creatine deficit could be seen as a distinctive pathological facet of this condition, and this might be approached with targeted therapies in aim to restore creatine homeostasis in target tissues. Among potential therapeutic candidates, guanidinoacetate (GAA) appears recently as a direct precursor of creatine that may favorably upregulate muscle and brain creatine concentration. Interestingly, GAA-creatine mixture was found to be superior than creatine itself to effectively improves bioenergetics in the human brain and muscle in healthy humans, perhaps due to the unique transportability features of this combination. Here, we plan to evaluate does creatine-GAA supplementation affects various biomarkers of sarcopenia in elderly.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-09-15
• Study First Submitted: 2020-11-26
• Study First Submitted QC: 2020-12-02
• Study First Posted: 2020-12-03
• Primary Completion: 2021-12-15
• Study Completion: 2021-12-31
• Status Verified: 2022-10
• Last Update Submitted: 2022-10-31
• Last Update Posted: 2022-11-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Age > 70 years
• Free of acute disorders

Exclusion Criteria

• History of dietary supplement use during the past 4 weeks

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Creatine-guanidinoacetic acid	Creatine-guanidinoacetic acid	2 grams of creatine and 2 grams of GAA Administered one dose two times per day on an empty stomach in the morning and at the evening
Inulin	Inulin	4 grams of inulin Administered one dose two times per day on an empty stomach in the morning and at the evening

Primary Outcome Measures

Name	Time	Method
Change in muscular strength	Baseline vs. 6 months post-intervention	Baseline vs. 6 months

Secondary Outcome Measures

Name	Time	Method
Change in serum creatine	Baseline vs. 6 months post-intervention	Baseline vs. 6 months
Change in muscle mass	Baseline vs. 6 months post-intervention	Baseline vs. 6 months
Change in cognitive performance evaluated with Mini-Mental State Exam test	Baseline vs. 6 months post-intervention	Baseline vs. 6 months
Change in muscle metabolites evaluated with MR spectroscopy	Baseline vs. 6 months post-intervention	Baseline vs. 6 months

Trial Locations

Locations (1)

Applied Bioenergetics Lab at Faculty of Sport and PE; 🇷🇸 Novi Sad, Vojvodina, Serbia